The liver is a target organ of life-threatening pathogens and prominently contributes to the
variation in drug responses and drug-induced liver injury among patients. Currently …

Introduction: Drug-induced liver injury (DILI) remains an increasingly recognized cause of
hepatotoxicity and liver failure worldwide. In 2017, we continued to learn about predicting …

In vitro preclinical drug-induced liver injury (DILI) risk assessment relies largely on the use of
hepatocytes to measure drug-specific changes in cell function or viability. Unfortunately, this …

Background Atabecestat, a potent brain penetrable BACE1 inhibitor that reduces CSF
amyloid beta (Aβ), was developed as an oral treatment for Alzheimer's disease (AD) …

Background Knowing the variability of blood coagulation responses to liver damage of
different origins can provide a key to curing liver tissues or to mitigating treatment side …

Long-term antiretroviral treatment (cART) increases the risk of glucose metabolism disorders
(GMDs). Genetic variation in drug-metabolizing enzymes and transporters may influence …

Introduction: Polymorphisms are the main genetic factors associated with toxicities of
antituberculosis drugs. This literature review summarizes the polymorphisms of the genes …

特异质型药物性肝损伤(IDILI) 是一种仅发生在少数易感人群中的严重药物不良反应,
其发生与患者的性别, 年龄, 基因和基础疾病有关, 具有较难预测, 无明显剂量依赖性和潜伏期长 …

Introduction Idiosyncratic, drug-induced liver injury (IDILI) continues to plague patients and
restrict the use of drugs that are pharmacologically effective. Mechanisms of IDILI are …

药物性肝损伤(drug induced liver injury, DILI) 是全球范围内常见的药品不良反应,
也是临床实践中一直尚未解决的问题, 其发病率和致死率逐年升高. DILI 的发生可能是多种因素 …